Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBITDA (2021 - 2025)

Historic EBITDA for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $51.4 million.

  • Krystal Biotech's EBITDA rose 1749.55% to $51.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $206.2 million, marking a year-over-year increase of 13339.14%. This contributed to the annual value of $206.2 million for FY2025, which is 13339.14% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's EBITDA is $51.4 million, which was up 1749.55% from $79.3 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's EBITDA ranged from a high of $80.6 million in Q3 2023 and a low of -$51.0 million during Q1 2022
  • In the last 5 years, Krystal Biotech's EBITDA had a median value of -$7.8 million in 2021 and averaged $4.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 22247.23% in 2022, then skyrocketed by 72636000.0% in 2025.
  • Krystal Biotech's EBITDA (Quarter) stood at -$22.0 million in 2021, then crashed by 42.59% to -$31.3 million in 2022, then skyrocketed by 131.02% to $9.7 million in 2023, then soared by 350.75% to $43.8 million in 2024, then increased by 17.5% to $51.4 million in 2025.
  • Its EBITDA stands at $51.4 million for Q4 2025, versus $79.3 million for Q3 2025 and $39.1 million for Q2 2025.